drugset
drugset / Trial / NCT03388216

Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab')2 Fragment (INM004) in Healthy Volunteers

NCT03388216 ↗

Phase 1 Completed 14 enrolled Inmunova S.A. Hospital Italiano de Buenos Aires · collab
RandomizedSequentialSingle-blindOther

Summary

This is Prospective Randomized Placebo controlled Single Blind Phase I study to evaluate the safety, tolerance and pharmacokinetics of the anti-Shiga toxin hyperimmune equine immunoglobulin F(ab')2 fragment (INM004) in healthy volunteers.

Timeline

Start
2017-12-16
Primary completion
2018-09-27
Completion
2018-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject INM004 Protein / enzyme biologic 2 mg/kg Other
Subject INM004 Protein / enzyme biologic 4 mg/kg Other

Indications

No indication recorded.